Volume 6 Supplement 1

2nd WAO International Scientific Conference (WISC 2012), Abstracts

Open Access

Asthma diagnosis and treatment – 1013. Six month follow up on pediatric patients with severe persistent allergic asthma after on eyear of omalizumb therapy

  • Tarun Choudhuri1
World Allergy Organization Journal20136(Suppl 1):P13

https://doi.org/10.1186/1939-4551-6-S1-P13

Published: 23 April 2013

Purpose

Anti-IgE antibody had been used in severe persistent allergic asthma in adults. However, its long-term efficacy in pediatric patients in India has not been reported.

Method

20 pediatric (12 male and 8 female) patients, with mean age of 8.5 having severe persistent allergic asthma, with recurrent exacerbations and on oral/IV steroids, prospectively received Omalizumab 150mg/300mg, depending on IgE & body weight for 6 month to 1 year,at B.R.Singh Hospital, Kolkata. Number of exacerbations, total dose of oral Steroids, use of rescue medications, ICS/LABA dose used were recorded at the baseline, 24 weeks, end of treatment and on 6 month follow up (between February 2011 and August 2012) and statistically analyzed.

Results

All 20 patients after anti-IgE therapy were followed-up for 6months.Significant reductions observed in total oral steroid use by six months -15.5mg (27.5mg vs. 12mg; 95%CI, p<0.001). Use of rescue medications with β2 agonists inhalerdecreased by -7.90 puffs (12.0 vs 4.10 puffs; 95%CI, p-value <0.001) at 24 weeks and by -13.67 puffs (13.67 vs 0.00 puffs; 95%CI, p-value <0.001) at 52 weeks (n=6). There was significant reduction in ICS dose at week 24 by -287.50 mcg (550.0 vs 262.50 mcg; 95%CI, p-value <0.001). By week 52 (n=6) ICS dose further declined to -458.33 mcg (750.0 vs 291.67 mcg; 95%CI, p-value <0.001). 15 (75%) patients had severe asthma symptoms at baseline,which came down to 6 (30%) (p<0.05), at week 24. Similarly 15 (75%) patients had unscheduled hospitalization at baseline, this figure came down to zero by week 24.

Conclusion

Use of anti-IgE antibody for 6 months to 1 year is well tolerated and led to overall significant improvement and stabilization of pediatric patients with severe persistent allergic asthma which was maintained at 6 months post treatment follow-up period.

Authors’ Affiliations

(1)
Pediatrics, Fiap

Copyright

© Choudhuri; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement